{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-8UN7DML4/55bb9992-8917-465c-b8e1-3bb1d7c495f2/HTML","dcterms:extent":"19 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-8UN7DML4/9c3ce566-78e8-4d33-9a7c-38ebf4d3e0b5/PDF","dcterms:extent":"203 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-8UN7DML4/a8459577-fbda-45ad-94c1-c2dec52aef4d/TEXT","dcterms:extent":"18 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-8UN7DML4","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2005","dc:creator":["Byrne Habič, Barbara","Mravljak, Janez","Pečar, Slavko"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"4 strani"},{"@xml:lang":"sl","#text":"letnik:56"},{"@xml:lang":"sl","#text":"str. 120-123"}],"dc:identifier":["ISSN:0014-8229","COBISSID:1799793","URN:URN:NBN:SI:doc-8UN7DML4"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"dušikov oksid"},{"@xml:lang":"sl","#text":"inhibitorji"},{"@xml:lang":"sl","#text":"L-arginin"},{"@xml:lang":"sl","#text":"sintaze"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Dušikov oksid III: zaviralci prekomernega nastajanja|"},"dc:description":[{"@xml:lang":"sl","#text":"Due to its radical nature nitric oxide can cause many illness and injuries of tissue by elevated concentrations at the site of its excessive formation. NO synthases - family of enzymes that catalyze conversion of arginine to NO and citrulline, are important therapeutic targets at the level of binding of substrate and cofactors as well as at the level of gene expression. Isophormically selective inhibitors of NO synthases represent considerable challenges for drug development"},{"@xml:lang":"sl","#text":"Dušikov oksid lahko zaradi svoje radikalske narave pri povišanih koncentracijah povzroči številna obolenja in poškodbe tkiva na mestu prekomernega nastanka. NO sintaze - družina encimov, ki katalizirajo pretvorbo arginina do NO in citrulina, so pomembne terapevtske tarče, tako na nivoju vezave substrata in kofaktorjev, kakor tudi na nivoju genske ekspresije. Velik izziv za načrtovanje in razvoj novih zdravil predstavljajo izoformno selektivni inhibitorji NO sintaz"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-8UN7DML4","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-8UN7DML4"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-8UN7DML4/9c3ce566-78e8-4d33-9a7c-38ebf4d3e0b5/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-8UN7DML4/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-8UN7DML4"}}}}